Recently initiated is a phase III randomized trial (MA.21 trial) of adjuvant chemotherapy for node-positive and high-risk node-negative, premenopausal and postmenopausal (£ 60 years) women with breast cancer who have
Maureen E. Trudeau, MD
Advertisement
Articles by Maureen E. Trudeau, MD
Advertisement
Latest Updated Articles
- Optimizing Adjuvant Breast Cancer Chemotherapy: Rationale for the MA.21 Study
Published: May 1st 2001 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
3
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
4
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
5
